| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-06 |
| mRNA | OSI-930 | CTRPv2 | pan-cancer | AAC | 0.18 | 1e-06 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.14 | 2e-06 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-06 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-06 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-06 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-06 |